Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind placebo-controlled phase III trial of extended-release dexmethylphenidate hydrochloride capsules in ADHD
CTR20242707Phase 3Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Dexmethylphenidate ER with Placebo (2 arms). Primary endpoint: Change from baseline in ADHD-RS-IV parent total score at end of double-blind treatment. Started Aug 2024; status: completed.
02
Drugs
dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on CTR20242707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242707.